This update reviews the remarkable progression in several cardiovascular gene transfer domains. The first chemical gene therapy protocols to stimulate angiogenesis in ischemic myocardium are discussed and both the great expectations as well as remaining hurdles are highlighted. In experimental models of restenosis and heart failure gene therapy shows promising results. Important questions regarding vector-related limitations and suboptimal in vivo delivery systems will require expeditious attention for gene therapy to become a more widely applicable option in cardiovascular diseases.
Introduction
Cancer patients for whom conventional treatment failed, might be more eager to try novel, and still incompletely Two years ago a focus on cardiovascular gene therapy validated treatments, while many patients with carwas published in this journal [1] , in which several reviews diovascular diseases and their doctors hesitate to consider were presented on different fields of cardiovascular medigene therapy. From this view point, patients suffering from cine, where gene therapy was emerging as a novel cardiac diseases with few or no therapeutic options, potential treatment modality. While some domains, includincluding cardiomyopathies and end-stage heart failure, ing therapeutic angiogenesis, have progressed at a remarkmight be better candidates for gene-based treatments in the able pace, other areas are still in the phase of in vitro and near future. Also, in some areas where gene therapy small animal research. On the other hand, the powerful appeared as a promising alternative for failing pharmacogene therapy technology has contributed significantly to a logical approaches, novel strategies are emerging. For better understanding of cardiovascular biology. Yet many instance, the introduction of brachytherapy in the prevenhurdles remain before gene therapy will make a noticeable tion and treatment of restenosis [3] and the advances in impact on the treatment of cardiovascular disease: vectorpercutaneous revascularization procedures might bear on related inflammation, limited expression span, suboptimal possible applications of gene therapy in its current state. delivery systems, and gene expression levels are among This update is not intended as a comprehensive overthe major concerns. Moreover, treatment strategies are view of current research in cardiovascular gene therapy, often based on mechanisms identified in small animal but rather as a concise update on new developments in models, the relevance of which for patient care needs areas that were highlighted in a former focused issue of careful consideration [2] .
Cardiovascular Research in 1997 [1] and with special emphasis on recent developments in gene therapy for angiogenesis and vasculoproliferative diseases.
and pharmacokinetic characteristics need a more detailed thrombosis in atherosclerotic rabbit arteries, but not in evaluation.
normal arteries, although transfection efficiency was simiTwo recent reviews have extensively covered the pros lar. . In contrast, NOS overexpression in atherosclerotic animal models and to patients relate to suboptimal delivery rabbit arteries might reduce mural inflammation and lipid systems, and vector-associated toxicity.
accumulation [45] , and there are indications that NO Essential cell-cycle regulatory proteins have been reduces neointimal hyperplasia after balloon angioplasty in targeted to prevent neointima formation, because smooth hypercholesterolemic rabbits [46] . muscle cell (SMC) proliferation is a key component in the The current widespread use of stents has virtually narrowing process in injured arteries [32] . In contrast, eliminated the problem of late constrictive remodeling, but restenosis in patients is a complex biological phenomenon remains associated with in-stent restenosis. In-stent reinvolving not only SMC proliferation, but also SMC stenosis is mainly caused by a SMC hyperproliferative migration and apoptosis, and matrix formation and degraresponse [47] and overexpression of NOS [48] or GAX dation, which contribute to remodeling. Proteins with [49] and chimeric DNA-RNA hammerhead ribozyme to pleiotropic effects on vascular cell functions might have an proliferating cell nuclear antigen [50] were capable of advantage to better target the response to vascular injury in significantly inhibiting stenosis in a porcine coronary patients than is the case with cell-cycle inhibitory proteins.
injury model. Coating stents with DNA or viruses may In this respect, overexpression of NOS [33], heme oxygenprovide an interesting alternative for local vascular gene ase (H01) [34] and C-type natriuretic peptide (CNP) [35] transfer, obviating the need for sophisticated and expensive have shown promising initial results, and deserve further delivery devices. High transfection efficiencies were reinvestigation.
ported with a DNA-eluting polymer-coated stent in porcine Local delivery via conventional interventional techcoronary arteries [51] . Furthermore, bioresorbable miniques remains the Achilles' heel of vascular gene therapy croporous intravascular stents can be impregnated with because of low transfection efficacy. Surgical methods, virus or DNA, providing a sustained-release local reservoir including local dwelling, are cumbersome or impossible to while still serving as an effective scaffold to the artery perform routinely. Adventitial delivery of adenoviral vec- [52] . A few years ago, seeding of genetically modified tors may cause less medial inflammation than intraluminal cells on stents was proposed as a promising technique [53] , delivery [36] , potentially reducing vector-induced inflambut no intracoronary applications of this approach have mation, but requires surgical procedures or perforating been reported so far. needle catheters [37] . Few novel devices have emerged Preventing neointimal growth in venous bypass grafts or since a previous review in this journal more than 2 years cardiac allografts might be a particularly attractive objecago [38] . Different approaches to optimize local gene tive for gene therapy, mainly because of the easy surgical delivery have been tested. In a comparative study, three access during tissue prelevation [54] . Two years ago, the intramural pressure-driven catheters and one mechanical authors of a review on gene therapy for the prevention of intramural catheter were compared in a porcine coronary vein graft failure [55] regretted the lack of interest for gene artery balloon-angioplasty model [39] . Three of the four therapy in this field. Since then, pressure-mediated delivery catheters tested (InfusasleeveE, CrescendoE and of E2F decoy oligonucleotide was tested in vein grafts InfiltratorE) demonstrated comparable efficiency as re- [56] , and was associated with decreased primary vein graft flected by vascular luciferase gene expression levels.
failure [57] . Reduction of neointimal growth in vein grafts Clearly, further development of interventional devices is has also been reported after overexpression of a constituessential to increase intracoronary gene transfer and to test tively active retinoblastoma protein [58] . A different the role of gene therapy for restenosis.
approach is to reduce SMC migration in vein grafts by Another question relates to gene transfer efficacy and overexpressing tissue inhibitors of metalloproteinases safety in complex, lipid rich atherosclerotic arteries.
(TIMP) 1 and 2 [59, 60] , the elastase inhibitor elafin [61] , Adenovirus-mediated gene transfer of the marker gene or the senescent cell-derived inhibitor sdi-1 [62] . Coronary human placental alkaline phosphatase was found equally arteriosclerosis in a mouse cardiac transplantation model effective in human atherosclerotic vessels and in normal was prevented by transfer of antisense oligonucleotides vessels in organ culture [40] . Anti-neointimal strategies against cyclin-dependent kinase CDK-2 [63] . have been successful in atherosclerotic rabbits [41] . HowFurther insight in the arterial response to balloon-anever, there might be some concern that adenoviral vectors gioplasty and stent implantation in patients will be necesmay induce thrombosis in atherosclerotic arteries. Lafont sary to identify the best targets to reduce restenosis. et al. [42] found that adenoviral gene transfer induced Continuous improvements in PTCA and stent implantation procedures, and the availability of intracoronary radiation atherosclerotic wall to reduce plaque progression or plaque will need to be balanced against the added benefit of gene rupture may therefore require less immunogenic vectors therapy for restenosis. Possible candidates for gene therapy [75] . in vasculoproliferative disease include in-stent restenosis, vein graft disease and transplant atherosclerosis.
Myocardial diseases 4. Hypercholesterolemia and atherosclerosis
The incidence of congestive heart failure is increasing [76] and despite advances in pharmacological treatment, Atherosclerotic cardiovascular disease remains the leadthe associated morbidity and mortality remain high. Thereing cause of death in western countries. Inherited disorders fore, gene-based strategies to improve cardiac function and of lipoprotein metabolism often lead to lipid levels that are overall clinical outcome might be particularly useful for difficult to control with conventional lipid-lowering drugs, these patients. making them particularly attractive targets for gene Gene-based approaches for heart failure are focusing on therapy. Four years ago, the first clinical study using ex proteins with a positive inotropic effect. Adenoviral gene vivo gene therapy for familial hypercholesterolemia was transfer of a vasopressin receptor in cardiomyocytes published [64] . Although significant reductions of LDL potentiated myocardial contraction by bypassing the delevels in three out of five patients tested were observed for sensitized b-adrenergic receptor signaling [77] , and overfour months after gene transfer, to date no other clinical expression of phospholamban [78] or b2-adrenergic restudies have been initiated.
ceptor [79] improved ventricular function in rodent hearts. Gene therapy for atherosclerosis and hyperlipidemia has Gene transfer vectors with extended transgene expression been focusing on modulating lipoprotein metabolism.
profiles are required to effectively target heart failure. In Successful attempts have been made to elevate HDL [65] , this respect, intramyocardial or intracoronary injection of and to decrease LDL [66] , VLDL [67] , and triglyceride recombinant adenovirus-associated vector encoding b-gallevels [68] . The effect of gene therapy on lipid profiles in actosidase resulted in significant transgene expression transgenic or knock-out mice lacking key components of levels for up to 8 weeks after the intervention, without the lipoprotein metabolism has been amply reviewed [69] .
evidence of myocardial inflammation or necrosis [80]. Gene-based techniques have also contributed to a better Myocardial infarction is a recent target for gene-based understanding of the pathogenesis of atherosclerosis [70] .
strategies, and reduction of reperfusion injury by overMore recently, research has shifted to explore the effect of expressing antioxidative proteins might be a valuable lipoprotein gene transfer on the development of the approach. Overexpression of extracellular superoxide disatherosclerotic process itself [71] . Although larger animal mutase (ec-SOD) attenuated stunning in ischemic rabbit models for atherosclerosis are under investigation, a proper hearts [81] , and adenovirus-mediated cardiac gene transfer interpretation of the effects of local genetic interventions of the antioxidant proteins SOD and catalase reduced on the atherosclerotic process, plaque stability and plaque contractile dysfunction after ischemic reperfusion in the progression remains very difficult. This is mainly due to neonatal mouse heart [82] . Delivery of decoy double the large variation and the unpredictability of lesions in stranded DNA against NFkB, a transcriptional factor that these animals. Nevertheless, gene-based strategies for regulates cytokine and adhesion genes, reduced the extent atherosclerosis and its complications will require exof myocardial infarction after reperfusion in the rat [83] . perimental scrutiny in relevant animal models before they However, gene transfer directly into infarcted myocardium can be considered for clinical applications.
suffers of low transfection efficiency when compared to Alternative approaches to reduce atherosclerosis and its non-infarcted normal myocardium [84] . Further expericomplications include the reduction of risk factors, e.g. the ments will have to determine the optimal delivery method inhibition of apolipoprotein(a) expression, a known risk and time of delivery of candidate genes for the reduction factor for atherosclerosis [72] . Novel non-lipoproteinof necrosis after myocardial infarction. based strategies, including overexpression of NOS with A completely different genetic approach to the treatment subsequent reduction of inflammatory cell infiltration and of heart failure and myocardial infarction, is transfer of ex lipid accumulation, might also be of interest [45] . The use vivo modified cells to the myocardium, as reviewed before of gene therapy to stabilize arterial plaques might be a [85] . Primary cells were forced to differentiate into muscle promising approach [73] . However, intravascular adminiscells after overexpression of MyoD, a transcription factor tration of the gene encoding b-galactosidase to brachial that drives myogenesis in non-muscle cells [86] . This arteries of hypercholesterolemic monkeys increased vessel could in theory modify the phenotype of the failing heart, wall inflammation and was associated with progression of provided that a sufficient number of cells can be implanted early atherosclerotic lesions [74] . This might have been without prohibitive toxicity. These obstacles have thus far caused by the vector itself, or by an immunological limited the applicability of the technique in large animal reaction to the transgene product. Gene transfer into the models.
Gene therapy for inherited myocardial diseases still the multifactorial etiology of the disease and the very suffers from many of the obstacles pointed out 2 years ago effective pharmacological therapy. [87] . Targeting a sufficient number of myocytes remains a In contrast, gene therapy for pulmonary hypertension challenge, and several approaches are being contemplated might offer novel perspectives as pharmacological treatto improve efficacy. Intracoronary injection is a fairly ment options are often limited. Adenovirus-mediated delivstraightforward approach, but leads only to very limited ery of constitutive NO Synthase via aerosol decreased both transduction, with only 0.3% of the cells transfected with acute [103] and chronic hypoxia-induced pulmonary hyan adenoviral vector [88] . Pericardial delivery is under pertension in rats [104] . As extended transgene expression investigation and has been combined with matrix degradis required for the treatment of chronic pulmonary hying proteins which facilitate the penetration of the visceral pertension, and because of uncertainties surrounding inpericardial barrier and markedly increase efficiency [89] .
flammatory reactions and immunogenicity of current vecAlso, retrograde delivery via the sinus venosus during tors, improvements in vector design are necessary before occlusion of the LAD has been shown to transduce 30- considering clinical applications. 50% of cardiomyocytes in the LAD region [90] .
Recently, gene-based approaches have also been proposed for the treatment of arrhythmias, both for acquired 8. New vectors rhythm abnormalities (e.g. in heart failure or myocarditis [91] ) and for inherited diseases (e.g. the long QT To date, DNA and oligonucleotide-based treatments syndromes [92] and familial atrial fibrillation [93] ). Imhave been very popular, probably due to less safety proved delivery systems and vectors with longer and more concerns as compared with viral vectors, and have been stable expression patterns will allow future investigations used in the first clinical trials. However, at least one in this field.
clinical trial has shown negative results, possibly because of very low transduction rates [29] . Nevertheless, oligonucleotide-based gene therapy strategies might have a 6. Thrombosis future [105] . Transfer of double stranded DNA that binds essential transcription factors inhibits the activation of In a review on gene therapy for arterial thrombosis [94] , endogenous gene transcription by these factors [106] . This the first experiments to deliver antithrombotic genes strategy has been successfully used in a clinical trial of (including hirudin, urokinase and cyclooxygenase) in prevention of vein graft failure [56] . New oligonucleotide injured arteries were described. To date, several new genes design can improve vector performance. Ribozymes for have been studied for their ability to reduce thrombosis.
instance not only bind to complementary RNA sequences, Adenoviral mediated overexpression of tPA [95] , thrombut also cleave the sequence enzymatically, thereby ambomodulin [96] , or tissue factor pathway inhibitor [97] plifying their effect, in contrast with conventional oligoreduced arterial thrombosis in injured rabbit arteries. These nucleotides. This novel method has been successfully used genetic approaches need to be weighed against developin experimental models of in-stent restenosis [50] . ments in antithrombotic molecules (GP IIbIIIa antagoAlthough clearly more effective than naked DNA, viral nists), which have significantly improved the safety / efficavectors still suffer from local and systemic toxicity. cy profile of these drugs in patients suffering from acute Replication-defective adenoviruses are generated using a coronary events [98] . Certainly, if local overexpression of helper cell-line that provides the missing E gene function.
1
antithrombotic gene products will further decrease bleedDue to possible recombination events between sequences ing complications associated with current systemic therapy in the vector and in the packaging helper cell-line, this and retain therapeutic efficiency, this approach might be a method does not entirely exclude the generation of revaluable alternative.
plication-competent adenoviral clones (RCA) during the manufacturing process. As RCA may contribute significantly to adenovirus-related local and systemic toxicity, 7. Hypertension the development of a new helper cell-line [107] for the generation of virus batches free of RCA has been a major Genetic strategies based on inhibition of components of step towards future clinical use of these vectors. Because the renin-angiotensin system are currently emerging to RCA have been implicated in the genesis of cartreat systemic hypertension [99, 100] . Intravenous injection diomyopathies, previous caveats on the use of viral vectors of the gene encoding atrial natriuretic peptide (ANP) not in myocardial disease [87] will need to be reconsidered. only attenuated hypertension in rats, but also decreased Thus vectors with additional deletions of adenoviral gene cardiac hypertrophy and renal injury [101] transfer is certainly feasible and has shown proof of or vectors with all of the viral genes deleted ('gutless' principle [102] , it seems nevertheless unlikely that it will vectors) have been constructed [111] and tested in animals, replace pharmacological therapy in the near future, given often with conflicting results. However, proper engineering of viral genes will likely result in adenoviral vectors with including hypoxia-induced [124] or shear stress-sensitive low toxicity and immunogenicity, and which will allow promoter sequences, or the viral vector envelope can be prolonged expression and repeated administration. modified to increase tissue specificity. The retroviral Adenovirus-associated virus (AAV)-derived vectors have envelope has been modified to incorporate the high affinity been proposed as a valuable alternative for cardiovascular collagen-binding domain from von Willebrand factor gene therapy. AAV-derived vectors have some advantages [125] , targeting the infection to the subendothelial matrix. over adenoviral vectors, mainly because of their nonAs vascular injury exposes collagen in the vessel wall, this pathogenic nature and absence of inflammation, allowing vector might be particularly interesting to target damaged stable, long-term expression [112] . Expression of a reportarteries. er gene was observed in rat carotid arteries up to 6 months after infection with AAV [113] . On the other hand, the AAV genome is small, only allowing room for about 4.8 kb 9. Conclusions of added DNA, and the difficulties of reproducible amplification procedures to yield high titer AAV-derived vectors Cardiovascular gene therapy has reached the clinical have limited this far the introduction of this vector in realm, and is likely to stay there. New clinical studies cardiovascular disease models. Nevertheless, efforts to using gene therapy in patients with cardiovascular disease improve infectious titer and yield [114] have initiated the are likely to emerge in the following years, particularly in first AAV cardiovascular gene therapy protocols in vitro the fields of restenosis, heart failure and angiogenesis. [115] and in vivo [80, 116] .
Further insights in cardiovascular molecular biology will at Retroviral vectors integrate into the host cell's genome the same time provide new potential targets for gene-based and result in a more stable and longer expression. They can strategies. Effective and safe delivery methods, together only infect dividing cells and can theoretically induce with new vectors for target-specific binding or synthetic malignant transformation by their random integration in formulations with high efficiency and safe profile will the host cell DNA. As for adenoviruses, one of the major undoubtedly lead to wider applicability of gene therapy in concerns with retroviral vectors is the possibility that a cardiovascular disease. Despite our present lack of knowlreplication-competent retrovirus is generated during the edge, intensified basic and applied research will certainly manufacturing process. Nevertheless, retroviral vectors are bring the first successes of cardiovascular gene-therapy currently used for cardiovascular gene therapy protocols protocols in the years to come. [99, 117] , and the advent of lentiviral vectors, which can infect non-dividing cells [118] is expected to facilitate its application for cardiovascular diseases. This is of parAcknowledgements ticular interest for cardiovascular gene therapy where long term expression is desirable. An alternative to increase P. Sinnaeve is a research assistant for the Fund for retroviral vector transfer efficiency is to stimulate cell Scientific Research-Flanders. S. Janssens is a Clinical proliferation in the target tissue. A limited partial liver Investigator of the Fund for Scientific Research-Flanders resection to stimulate the rate of hepatocyte turn-over was and the recipient of a chair supported by Zeneca Pharmaperformed in combination with portal vein injection of ceuticals Inc. cytotoxic thymidine kinase gene followed by ganciclovir treatment. This combined suicidal gene transfer and surgical intervention resulted in improved hepatic uptake and References expression of the desired transgene [119] .
Directing gene transfer vectors to the target cells exclu- sively might also reduce toxicity and increase efficiency. against c-myc bound to microbubbles, followed by trans- sion, as already described two years ago [121] . These new promoters may include cell-specific promoters including the smooth muscle actin promotor [122] or the a-myosin phVEGF165 after intramuscular gene transfer promotes collateral heavy chain promoter [123] 
